Clincal research in ovarian cancer: consensus recmomendations from the Gynecologic Cancer InterGroup
Ignace Vergote 1, Antonio Gonzalez-Martin 2, Domenica Lorusso 3, Charlie Gourley 4, Mansoor Raza Mirza 5, Jean-Emmanuel Kurtz 6, Aikou Okamoto 7, Kathleen Moore 8, Frédéric Kridelka 9, Iain McNeish 10, Alexander Reuss 11, Bénédicte Votan 12, Andreas du Bois 13, Sven Mahner 14, Isabelle Ray-Coquard 15, Elise C Kohn 16, Jonathan S Berek 17, David S P Tan 18, Nicoletta Colombo 19, Rongyu Zang 20, Nicole Concin 21, Dearbhaile O’Donnell 22, Alejandro Rauh-Hain 23, C Simon Herrington 24, Christian Marth 25, Andres Poveda 26, Keiichi Fujiwara 27, Gavin C E Stuart 28, Amit M Oza 29, Michael A Bookman 30, participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research
Lancet Oncol. 2022 Aug;2(8):e374-e384.
Nonepithelial ovarian cancer – the current clinical practice in the Nordic countries. Survey from the surgical subcommitte of the Nordic society of gyncological oncology (NSGO)
Cristina Daviu 1, Jan Blaakaer 2 , Ane Gerda Z Eriksson3 , Jørn Herrstedt 4, M P Vandborg5, Anne Mette Odgaard Rasmussen6 , Katrine Fuglsang 7
Acta Oncol. 2022 Aug;61(8):939-945.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGrpuå-Symptom Benefit Study
Yeh Chen Lee 1, Madeleine T King 2, Rachel L O’Connell 3, Anne Lanceley 4, Florence Joly 5, Felix Hilpert 6, Alison Davis 7, Felicia T Roncolato 8, Aikou Okamoto 9, Jane Bryce 10, Paul Donnellan 11, Amit M Oza 12, Elisabeth Avall-Lundqvist 13, Jonathan S Berek 14, Jonathan A Ledermann 15, Dominique Berton 16, Jalid Sehouli 17, Amanda Feeney 18, Marie-Christine Kaminsky 19, Katrina Diamante 20, Martin R Stockler 21, Michael L Friedlander 22, GCIG Symptom Benefit Group
INT J Gynecol Cancer. 2022 Jun 6;32(6)761-768.
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander 1, J Rau 2, C K Lee 3, W Meier 4, A Lesoin 5, J-W Kim 6, A Poveda 7, M Buck 8, G Scambia 9, M Shimada 10, F Hilpert 11, M T King 12, P Debruyne 13, A Bologna 14, S Malander 15, B J Monk 16, E Petru 17, P Calvert 18, T J Herzog 19, C Barrett 20, A du Bois 21
Ann Oncol . 2018 Mar 1;29(3):737-743.
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King 1 2 3, Martin R Stockler 4 5, Rachel L O’Connell 5, Luke Buizen 5, Florence Joly 6 7, Anne Lanceley 8, Felix Hilpert 9 10, Aikou Okamoto 11 12, Eriko Aotani 13 14, Jane Bryce 15 16, Paul Donnellan 17, Amit Oza 18 19, Elisabeth Avall-Lundqvist 20 21 22, Jonathan S Berek 23 24, Jalid Sehouli 10 25, Amanda Feeney 26, Dominique Berton-Rigaud 7 27, Daniel S J Costa 28 29, Michael L Friedlander 4 30, GCIG Symptom Benefit group
Qual Life Res . 2018 Jan;27(1):59-74.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
M K Wilson 1, E Pujade-Lauraine 2, D Aoki 3, M R Mirza 4, D Lorusso 5, A M Oza 6, A du Bois 7, I Vergote 8, A Reuss 7, M Bacon 9, M Friedlander 1, D Gallardo-Rincon 10, F Joly 2, S-J Chang 11, A M Ferrero 12, R J Edmondson 13, P Wimberger 14, J Maenpaa 4, D Gaffney 15, R Zang 16, A Okamoto 3, G Stuart 17, K Ochiai 3, participants of the Fifth Ovarian Cancer Consensus Conference
Ann Oncol . 2017 Apr 1;28(4):727-732
Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.
Rosalind M Glasspool 1, Antonio González Martín, David Millan, Domenica Lorusso, Elisabeth Åvall-Lundqvist, Jean A Hurteau, Alison Davis, Felix Hilpert, Jae-Weon Kim, Jérôme Alexandre, Jonathan A Ledermann
https://pubmed.ncbi.nlm.nih.gov/25126954/
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)
Philipp Harter 1, David Gershenson, Catherine Lhomme, Fabrice Lecuru, Jonathan Ledermann, Diane M Provencher, Delia Mezzanzanica, Michael Quinn, Johanna Maenpaa, Jae-Weon Kim, Sven Mahner, Felix Hilpert, Klaus Baumann, Jacobus Pfisterer, Andreas du Bois
https://pubmed.ncbi.nlm.nih.gov/25341581/
Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.
Nicholas Simon Reed 1, Eva Gomez-Garcia, Dolores Gallardo-Rincon, Brigitte Barrette, Klaus Baumann, Michael Friedlander, Ganessan Kichenadasse, Jae-Weon Kim, Domenica Lorusso, Mansoor Raza Mirza, Isabelle Ray-Coquard
https://pubmed.ncbi.nlm.nih.gov/25341578/
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.
Martee L Hensley 1, Brigitte A Barrette, Klaus Baumann, David Gaffney, Anne L Hamilton, Jae-Weon Kim, Johanna U Maenpaa, Patricia Pautier, Nadeem Ahmad Siddiqui, Anneke M Westermann, Isabelle Ray-Coquard
https://pubmed.ncbi.nlm.nih.gov/25341583/
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Dominique Berton-Rigaud 1, Mojgan Devouassoux-Shisheboran, Jonathan A Ledermann, Mario M Leitao, Matthew A Powell, Andres Poveda, Philip Beale, Rosalind M Glasspool, Carien L Creutzberg, Philipp Harter, Jae-Weon Kim, Nicholas Simon Reed, Isabelle Ray-Coquard
https://pubmed.ncbi.nlm.nih.gov/25341582/
Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.
Jubilee Brown 1, Michael Friedlander, Floor J Backes, Philipp Harter, Dennis M O’Connor, Thibault de la Motte Rouge, Domenica Lorusso, Johanne Maenpaa, Jae-Weon Kim, Meghan E Tenney, Michael J Seckl
https://pubmed.ncbi.nlm.nih.gov/25341580/
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors
Isabelle Ray-Coquard 1, Jubilee Brown, Philipp Harter, Diane M Provencher, Peter C Fong, Johanna Maenpaa, Jonathan A Ledermann, Gunter Emons, Dominique Berton Rigaud, Rosalind M Glasspool, Delia Mezzanzanica, Nicoletta Colombo
https://pubmed.ncbi.nlm.nih.gov/25341579/
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serouscarcinomas.
Charlie Gourley 1, John Farley, Diane M Provencher, Sandro Pignata, Linda Mileshkin, Philipp Harter, Johanna Maenpaa, Jae-Weon Kim, Eric Pujaide-Lauraine, Rosalind M Glasspool, Isabelle Ray-Coquard, David Gershenson
https://pubmed.ncbi.nlm.nih.gov/25341587/
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary
Aikou Okamoto 1, Rosalind M Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki, Ikuo Konishi, Alan Covens, Jonathan Ledermann, Delia Mezzanzanica, Christopher Steer, David Millan, Iain A McNeish, Jacobus Pfisterer, Sokbom Kang, Laurence Gladieff, Jane Bryce, Amit Oza
https://pubmed.ncbi.nlm.nih.gov/25341576/
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M.
Ann Oncol. 2013 Apr;24(4):937-43
Clinical trials in recurrent ovarian cancer.
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup.
Int J Gynecol Cancer. 2011 May;21(4):771-5.
First-Line Therapy in Ovarian Cancer Trials.
Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; on behalf of the Gynecologic Cancer InterGroup.
Int J Gynecol Cancer. 2011 May;21(4):756-762.
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A,Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A. Vermorken J.
Int J Gynecol Cancer. 2011 Feb;21(2):419-423
Prognostic nomogram to predict progression-free survival in patients with platinum- sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M
https://pubmed.ncbi.nlm.nih.gov/21915127/
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ.
J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42.
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian can
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J,
Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M.
Br J Cancer. 2011 Jul 26;105(3):360-5.
European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Pharmaceutical Companies
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J,
Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A,Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups
Int J Gynecol Cancer 2010;20: 476-478
Clinical trials in gynecological cancer.
Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT; Gynecologic Cancer Intergroup.
Int J Gynecol Cancer. 2007 May-Jun;17(3):547-56
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart J, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E.
J Clin Oncol. 2006 Jan 1;24(1):45-51
Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.
Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I.
Ann Oncol. 2005 Oct;16 Suppl 8:viii13-viii19
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference(GCIG OCCC 2004).
duBois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade- Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC.
Ann Oncol. 2005;16 Suppl 8:viii7-viii12.
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCIC-CTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI; SGCTG; RTOG; NCI-US.
Ann Oncol. 2005;16 Suppl 8:viii36-viii38.
History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004
Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J.
Ann Oncol. 2005;16 Suppl 8:viii5-viii6.
The Gynecologic Cancer Intergroup (GCIG): history and current status
Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M; GCIG; AGO-OVAR; ANZGOG; EORTC-GCC; GEICO; GINECO; GOG; JGOG; MRC; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG.
Ann Oncol. 2005;16 Suppl 8:viii39-viii42
Integration of new or experimental treatment options and new approaches to clinical trials
Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U; ANZGOG; AGO-OVAR; NSGO; GOG; EORTC; GEICO; MRC/NCRI; NCIC-CTG; IGCS; GINECO; NCI-US; SGCTG.
Ann Oncol. 2005;16 Suppl 8:viii30-viii35
New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J.
J Natl Cancer Inst. 2004 Mar 17;96(6):487-8.
Pognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore E, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen , Trope CG.
Lancet. 2001 Jan 20;357(9251):176-82.
New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB.
J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5.
Epithelial ovarian cancer (advanced stage): consensus conference (1998)
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen K, Vergote I, Vermorken JB, Willemse PH.
Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83.
Advanced epithelial ovarian cancer: 1998 consensus statements
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al.
Ann Oncol. 1999;10 Suppl 1:87-92
Intergroup collaboration in ovarian cancer: a giant step forwar
Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C, Swenerton K, Harper P, Vermorken JB.
Ann Oncol. 1999;10 Suppl 1:83-6.
Advanced epithelial ovarian cancer: 1993 consensus statement Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Huinink W, van der Burg ME, Calvert AH, Conte PF, Dauplat J, et al
Ann Oncol. 1993;4 Suppl 4:83-8.